2023-04-27
NextCell publishes its Interim Report 2 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2022 – February 28, 2023 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Read moreRead more2023-04-26
Breakthrough multiplication of blood stem cells
NextCell Pharma AB (“NextCell” or the “company") announces that the FDA has approved a product of multiplied stem cells from umbilical cord blood. It is a breakthrough that could lead to increased interest in saving stem cells for private use, where Cellaviva is the market leader in Scandinavia. Cellaviva is a part of NextCell with offices in Stockholm and Copenhagen.
NextCell Pharma AB (“NextCell” or the “company") announces that the FDA has approved a product of multiplied stem cells from umbilical cord blood. It is a breakthrough that could lead to increased interest in saving stem cells for private use, where Cellaviva is the market leader in Scandinavia.
Read moreRead more2023-04-18
NextCell invited speaker at European Wound Management Association Meeting in Milan
NextCell Pharma AB´s ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invited to give a presentation at the EWMA meeting in Milan, showcasing NextCell´s phase II clinical data with their investigative medicinal product, ProTrans, in slowing the progression of type-1 diabetes.
NextCell Pharma AB´s ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invited to give a presentation at the EWMA meeting in Milan, showcasing NextCell´s phase II clinical data with their investigative medicinal product, ProTrans, in slowing the progression of type-1 diabetes.
Read moreRead more2023-03-28
NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted
NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.
Read moreRead more2023-03-21
NextCell’s CSO elected to ISCT European Regional Secretary
NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been officially elected to the position of European Regional Secretary for the International Society for Cell and Gene Therapy.
Read moreRead more2023-03-07
NextCell’s CSO nominated for ISCT European Regional Secretary
NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been nominated for the position of European Regional Secretary for the International Society for Cell and Gene Therapy.
Read moreRead more2023-01-26
NextCell publishes its Interim Report 1 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Ma
Read moreRead more2023-01-25
ProTrans study in COVID-19 expanded to include treatment of severe pneumonia induced by influenza A, RSV and HMP virus
NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has approved the expansion of their Swedish COVID-19 study, to include patients with severe pneumonia due to influenza A, respiratory syncytial virus (RSV) and human metapneumovirus (HMP). The treatment is aimed
Read moreRead more